Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis
2018
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent Era
2016
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
2021
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Regulation of microRNA function in animals
2018 Standout
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
2022
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
2017
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin
2020 StandoutNobel
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
From non-A, non-B hepatitis to hepatitis C virus cure
2015
Contribution of platelets to tumour metastasis
2011 Standout
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Burden of liver diseases in the world
2018 Standout
Hepatitis C: The next 25 years
2014 StandoutNobel
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges
2018
Hepatitis C
2015
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
2006
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Hepatocellular carcinoma
2012 Standout
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2018
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Hepatitis C Treatment: The Data Flood Goes on—An Update From the Liver Meeting 2014
2015
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma
2016
Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients
2018
Bifidobacterium Lactis sp. 420 Up-Regulates Cyclooxygenase (Cox)-1 and Down-Regulates Cox-2 Gene Expression in a Caco-2 Cell Culture Model
2005
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
Molecular and cellular mechanisms of liver fibrosis and its regression
2020
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)
2016
The natural history of recurrent hepatitis C and what influences this
2008
Liver Transplantation for Hepatocellular Carcinoma
2008
The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
2020
Non-alcoholic fatty liver disease
2021 Standout
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
2018
Pros and Cons: Usage of organs from donors infected with hepatitis C virus – Revision in the direct-acting antiviral era
2015
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
2018
Liver Transplantation in Children with Sickle-Cell Disease†
2007
Treatment of hepatitis C in difficult-to-treat patients
2015
Sickle-cell disease
2010 Standout
Global burden of liver disease: 2023 update
2023 Standout
Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C–Related Hepatocellular Carcinoma
2014
Resection and Liver Transplantation for Hepatocellular Carcinoma
2005
Therapeutic Landscape for NAFLD in 2020
2020
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma
2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
2017
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
2013 Standout
Simultaneous “One Pot” Expressed Protein Ligation and CuI‐Catalyzed Azide/Alkyne Cycloaddition for Protein Immobilization
2011 StandoutNobel
Surgical approach for hepatitis C virus-related hepatocellular carcinoma
2015
Probiotics and immunity: A fish perspective
2010 Standout
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation
2015
Antibiotics for the treatment of hepatic encephalopathy
2013
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
2019
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
Hepatocellular Carcinoma
2011 Standout
Hepatocellular carcinoma
2022 Standout
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
2016
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation
2004
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
2021
Hepatocellular Carcinoma
2019 Standout
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
2009
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus
2017
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
2017
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
2015
Video capsule endoscopy in inflammatory bowel disease
2010
Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib
2018
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
2019
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
2016
Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation
2017
NS5B polymerase inhibitors in phase II clinical trials for HCV infection
2017
Surface-Enhanced Raman Spectroscopy for Bioanalysis: Reliability and Challenges
2018 Standout
Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis
2017
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
2017
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
2021
Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B
2014 StandoutNobel
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
2013
Seed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B Interaction
2014 StandoutNobel
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 Standout
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
2017
Second‐wave IFN ‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir
2013
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
2020
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers
2011
Ultrasound Elastography: Review of Techniques and Clinical Applications
2017 Standout
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
2013
Works of Parvez Mantry being referenced
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
2017
Survival Outcomes in Liver Transplantation for Hepatocellular Carcinoma, Comparing Impact of Hepatitis C Versus Other Etiology of Cirrhosis†
2007
Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study
2017
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma
2007
Living Donor and Deceased Donor Liver Transplantation for Autoimmune and Cholestatic Liver Diseases—An Analysis of the UNOS Database
2010
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
2016
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
2020
Comparative Analysis of Outcomes in Living and Deceased Donor Liver Transplants for Primary Sclerosing Cholangitis
2009
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
2014
Liver Transplantation in Sickle Cell Anemia: A Case of Acute Sickle Cell Intrahepatic Cholestasis and a Case of Sclerosing Cholangitis
2005
What we have learned from 5 cases of permanent capsule retention
2006
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
2020
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review
2015
Rifaximin for the Treatment of Hepatic Encephalopathy
2010
IMPACT OF HEPATITIS C VIRAL INFECTION IN PRIMARY CADAVERIC LIVER ALLOGRAFT VERSUS PRIMARY LIVING-DONOR ALLOGRAFT IN 100 CONSECUTIVE LIVER TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS
2004
Celecoxib Associated Esophagitis
2003
Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)
2014
UPPER GASTROINTESTINAL DISORDERS IN PATIENTS WITH HEPATITIS C
2004
LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study
2015
Prevention of allograft HCV recurrence with peri‐transplant human monoclonal antibody MBL ‐HCV 1 combined with a single oral direct‐acting antiviral: A proof‐of‐concept study
2016
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis
2015
Use of staging and scoring systems in hepatocellular carcinoma (HCC): Lessons from U.S. regional analysis of the GIDEON registry.
2014
MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection
2017